Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
These findings suggest that early discontinuation may diminish the cardiovascular benefits of GLP-1 RAs, underscoring the importance of treatment persistence when evaluating real-world outcomes
And the question is when, if at all, theyre going to take them out and assert them against Hims. Lets just say a compounding pharmacy, a 503B pharmacy, makes a few dozen injections here or there
Slower escalation means fewer side effects but a longer wait for full therapeutic effects
Phase 3 outcomes (2026): TRIUMPH-1 (May 2026, n=2,339) demonstrated 28.3% mean weight loss at 12mg weekly the largest published Phase 3 result of any GLP-1 class compound to date, exceeding tirzepatide (22.5% in SURMOUNT-1) and semaglutide (14.9% in STEP-1) at comparable timepoints
